Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326649 · ClinicalTrials.gov registry record
Noninvasive Measurement of CO Using Impedance Cardiography in Patients With CHD
A clinical trial, sponsored by University of California, San Diego.
- Completed
- Registry status
- 21
- Enrollment target
NCT02326649: Completed study, sponsored by University of California, San Diego.
NCT02326649 is a clinical trial that has completed, run by University of California, San Diego. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02326649 has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
This study will test the capability of a non-invasive instrument (the PhysioFlow impedance cardiography instrument) to measure cardiac output in patients with congenital heart disease (CHD). This instrument works by placing electrodes on the skin of a patient and measuring electrical impedance through the chest, which is proportional to blood volume and blood flow at any given time. The instrument has been validated in patients with structurally normal hearts, but in the only two studies using it for patients with CHD, it was deemed too inaccurate for clinical use. The manufacturer of the device would require access to data on the patients in order to improve its accuracy, and that has not been feasible thus far. This study would begin by comparing cardiac output based on the PhysioFlow monitor to standard techniques, then after possible changes to the instrument to enhance accuracy, would test the instrument again in the same way.
Primary Outcome
Mean difference in stroke volume (SV) between CMR and SMIC measurements in ml
Interventions
- DEVICE Physioflow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-03 |
What the finished NCT02326649 record still lists
NCT02326649 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Physioflow is the first listed.
NCT02326649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02326649 about?
NCT02326649 is a clinical study titled "Noninvasive Measurement of CO Using Impedance Cardiography in Patients With CHD". This study will test the capability of a non-invasive instrument (the PhysioFlow impedance cardiography instrument) to measure cardiac output in patients with congenital heart disease (CHD). This instrument works by placing electrodes on the skin of a patient and measuring electrical impedance throu...
What is the current status of trial NCT02326649?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2014-12. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02326649?
The interventions under investigation include: Physioflow (DEVICE).
Who is sponsoring clinical trial NCT02326649?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia